Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Call Transcript February 13, 2025
Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-1.32.
Operator: Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A...
